Lena Söderström, CEO of Isconova commented: “The prize is an appreciated recognition and an inspiration to us in our efforts to establish Isconova as a leading provider of vaccine adjuvants”

About Isconova AB
Isconova AB develops, manufactures, out-licenses and sells state-of-the art adjuvants for the creation of highly effective antigen delivery systems for vaccine development, antibody production and immune response studies. In addition, the company sells reagents for formulating custom made complexes for the end-user. The products are based on the proprietary ISCOM technology platform and the market is global. Isconova was founded in 2000 as a spin-off from the Swedish University of Agricultural Science in Uppsala to further develop the ISCOM technology and make it commercially available and accessible.
For more information, visit Isconova’s website: www.isconova.se

Contact
Isconova AB, Uppsala, Sweden
Lena Söderström, CEO
Phone: +46 18 57 24 00
E-mail: lena.soderstrom@isconova.se

[1] http://www.bonapostulata.se/

The AbISCO® adjuvant consistently induces the highest proliferation index and high production levels of antibodies.

In addition to the data retrieved in mice, an ongoing Phase I study in Bergen shows similar encouraging performance in man. The preliminary unpublished results from the human clinical trial shows that the Matrix-M adjuvanted H5N1 vaccine induce high numbers of antibody producing cells and high frequency of multifunctional CD4+ Th1 cells, even at a low dose of antigen. The presence of multifunctional T cells has been described as indicative for protective T cell responses.

Lena Söderström, Chief Executive Officer of Isconova commented: “The dose-sparing characteristics of Isconova´s Matrix M, its safety profile and level of efficacy makes this state-of-the-art adjuvant an excellent candidate for modern vaccine formulations which can meet the challenges of future pandemic influenza threats. We are very excited about these results”.

About Isconova AB
Isconova AB develops, manufactures, out-licenses and sells state-of-the art adjuvants for the creation of highly effective antigen delivery systems for vaccine development, antibody production and immune response studies. In addition, the Company sells reagents for formulating custom made complexes for the end-user. The products are based on the proprietary Immune Stimulating Complex (ISCOM) technology platform and the market is global. Isconova was founded in 1999 as a spin-off from the Swedish University of Agricultural Science in Uppsala to further develop the Immune Stimulating Complex (ISCOM) technology and make it commercially available and accessible.
For more information, visit Isconova’s website: www.isconova.se

Contact
Isconova AB, Uppsala, Sweden
Lena Söderström, CEO
Phone: +46 18 57 24 00
E-mail: lena.soderstrom@isconova.se

[1]. Madhun A. S., Haaheim L. R., Nilsen M.V., Cox R. J. (2009 dec.) Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4(+) cells and strong antibody responses in mice, Vaccine , In Press

Lena Söderström is currently CEO at Kibion AB. Kibion AB is a company focused on the commercialization of H. pylori diagnostic products and is a subsidiary of the publicly listed company Orexo AB. Kibion has products commercialized on a global basis. Lena has built Kibion from ‘start up’ to a business operating through distributors in the global marketplace. The company revenues have increased 10-fold during this period. Lena Söderström has more than 20 years of management experience in the international pharmaceutical and medical device industry and vast experience in development as well as production and marketing. Before joining Kibion she was Director Business Development at Fresenius Kabi AB. “We are very pleased that Lena is taking on the challenge of further developing Isconova into a major adjuvant company for both human and veterinary vaccines. She has the knowledge and the driving force needed to increase growth and build strong operations based on Isconova’s unique adjuvant technology platform”, commented Lars Gardö, Chairman of Isconova AB.

Commenting on her appointment, Lena Söderström said; “I have been extremely impressed with Isconova’s unique and high quality technology and team as well as its strong relationships with global healthcare corporations. I am delighted to be joining Isconova at this exciting time as the Company is driving its adjuvant technology while establishing additional relationships that will deliver on the commercial promise that Isconova’s technology offers as a novel adjuvant technology.”

After 7 years as CEO, Bengt Falk has decided to leave the company. During Bengt Falk’s management the Company has developed into a leading manufacturer of adjuvant for veterinary vaccines and the foundation is laid for the development of the company’s technology into human vaccines through the successful Phase 1 trial of a pandemic Influenza vaccine and significant license and supply deals, “I would like to thank Bengt Falk for his considerable efforts and contributions to Isconova’s success to date.” said Lars Gardö.

About Isconova AB

Isconova AB develops, manufactures and sells ready-made AbISCO® adjuvants for the creation of highly effective antigen delivery systems for vaccine development. In addition, the company sells licenses and manufactures adjuvant for veterinary and human vaccine purposes based on its proprietary Immune Stimulating Complex technology. Currently five vaccines for horses, dogs and cattle are on market through partners such as Schering-Plough and Pfizer and one human vaccine is in clinical phase development. Isconova has 20 employees, is located in Uppsala Science Park and was founded in 1999 as a spin-off from the Swedish University of Agricultural Sciences in Uppsala.

Contact: Bengt Falk
Isconova AB, Dag Hammarskjöld väg 54 A
751 83 Uppsala, Tel +4618572402 or +46703022254

Uppsala, Sweden, July 20 2009 – Isconova [www.isconova.com] is a pioneer in the discovery and development of state-of-the-art vaccine adjuvants based on Immune Stimulating Complex technology, which allows development of innovative and more efficacious vaccines. Isconova announced today that the PANFLUVAC consortium[1] consisting of eight European research partners has completed the first stage of their phase I clinical trial in healthy volunteers, using a pandemic A/H5N1 virosomal vaccine formulated with Isconova’s Matrix-M^TM adjuvant.

The clinical trial was conducted in 60 subjects at the University of Bergen, Norway to assess the safety, tolerability and immunogenicity of the pandemic H5N1 influenza vaccine. The primary safety and tolerability endpoints of the Phase I study are the lack of local and systemic adverse events and tolerability of the parenterally administered vaccine.

The virosomal H5N1 influenza vaccine formulated with the Matrix-M^TM adjuvant was well tolerated and no serious adverse events were reported. The evaluation of the vaccine immunogenicity is ongoing.

 ”Isconova is delighted that the PANFLUVAC consortium has entered into a healthy volunteer Phase I study with the pandemic A/H5N1 virosomal vaccine formulated with Isconova’s Matrix-M^TM adjuvant. This is an important milestone for Isconova and we look forward to continue our collaboration with the PANFLUVAC consortium and to see the outcome of this study in 2010″, commented Dr Bengt Falk, Chief Executive Officer of Isconova.

About Isconova AB

Isconova AB develops, manufactures and sells ready-made AbISCO® adjuvants for the creation of highly effective antigen delivery systems for vaccine development, antibody production and immune response studies. In addition, the company sells licenses and manufactures adjuvant for veterinary purposes based on Immune Stimulating Complex technology. Currently 5 vaccines for horses, dogs and cattle are on market through partners such as Sheering Plough and Pfizer. Isconova was founded in 1999 as a spin-off from the Swedish University of Agricultural Science in Uppsala.

For more information, visit Isconova’s website: www.isconova.se or contact

For more information please contact Bengt Falk, +4618572402 or + 46703022254

Isconova AB, Uppsala, Sweden

[1] The PANFLUVAC consortium is funded by the European Union through the Framework 6 project, contract No. 044115, and comprises eight academic and commercial research groups covering several different disciplines. Through PANFLUVAC, a new human vaccine against avian H5N1 influenza virus has been developed and pre-clinically evaluated, with the current efforts focusing on Phase I clinical evaluation. This PANFLUVAC research project is demonstrating a European capacity to produce a safe and efficacious vaccine against highly pathogenic avian influenza virus. The PANFLUVAC consortium consists of Institute of Virology and Immunoprophylaxis (IVI, Switzerland (Project Co-ordinator), Crucell (the Netherlands), National Institute for Biological Standards and Control (NIBSC, now part of HPA, UK), Retroscreen Virology Ltd (UK), Influenza Centre of the University of Bergen (Norway), Respiratory Unit of the Health Protection Agency Colindale (UK), National Influenza Centre of the Istituto Superiore di Sanita (Italy), and Helmholtz-Zentrum für Infektionsforschung (Germany).

The new formulations increase the adjuvant performance safety window by an order of magnitude, a result that has been verified in several species. The increased performance and safety is not limited to saponin-based formulations, it is also suitable for combination with other adjuvant/immune-modulator formulations.

Dr Wells has a long and outstanding scientific and business career within the Pharmaceutical and Animal Health Industry. He has just retired as Global Head of R&D at Novartis Animal Health. Having Dr Wells as a director will further strengthen Isconova’s unique combination of knowledge, experience and commercial insight in providing products and expertise within the vaccine field.

Isconova, a Swedish vaccine technology company, and Biogenuix, a provider of marketing, distribution and CRO solutions to the global biotech and healthcare market, today announced the signing of a distribution agreement. Under the terms of the agreement Biogenuix will distribute and promote AbISCO® adjuvants in India.

About Isconova AB

Isconova AB develops, manufactures and sells ready-made AbISCO® adjuvants for the creation of highly effective antigen delivery systems for vaccine development, antibody production and immune response studies. In addition, the company sells reagents for formulating custom made complexes for the end-user. The products are based on the proprietary ISCOM technology platform and the market is global. Isconova was founded in 1999 as a spin-off from the Swedish University of Agricultural Science in Uppsala to further develop the ISCOM technology and make it commercially available.

For more information, visit Isconova’s website: www.isconova.se

About Biogenuix Medsystems Pvt. Ltd.

Biogenuix, headquartered at New Delhi, India was founded by a team of professionals having more than two decades of sales and marketing experience with fortune 500 multinational companies.Biogenuix provides marketing, distribution and CRO solutions to global biotech and healthcare companies having an interest in the growing Indian market. Biogenuix is a B2C & B2B solutions company. At, Biogenuix, we believe that all our business partners are unique in terms of their product offerings, global business strategy and may have varied levels of interests in the growing Indian market.

For more information, visit Biogenuix’s website: http://www.biogenuix.com/

Biogenuix Medsystems Pvt. Ltd.

Phone : +91-11-25612008

Email : contact@biogenuix.com

Isconova AB, Uppsala, Sweden

Phone: +46 18 57 24 00

Email: abisco@isconova.se